Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Public ClinicalTrials.gov record NCT05198934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator's choice (trifluridine and tipiracil, or regorafenib).
Study identification
- NCT ID
- NCT05198934
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2022 (Actual)
- Primary completion
- Jul 16, 2025 (Actual)
- Completion
- Apr 14, 2026 (Actual)
- Last update posted
- Jul 22, 2026
2022 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Birmingham | Alabama | 35209 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Johns Hopkins University School of Medicine | Washington D.C. | District of Columbia | 20016 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Lakes Research LLC | Miami Lakes | Florida | 33014 | — |
| Northwest Georgia Oncology Centers PC | Marietta | Georgia | 30060 | — |
| University of Michigan | Ann Arbor | Michigan | 48106-0995 | — |
| Revive Research Institute | Farmington Hills | Michigan | 48334 | — |
| Sparrow Clinical Research Institute | Lansing | Michigan | 48912 | — |
| Revive Research Institute | Sterling Heights | Michigan | 48314 | — |
| Upstate University Hospital | Syracuse | New York | 13210 | — |
| White Plains Hospital Center for Cancer Care | White Plains | New York | 10601 | — |
| Moses H Cone Memorial Hospital | Greensboro | North Carolina | 27403 | — |
| The Mark H Zangmeister Center | Columbus | Ohio | 43210 | — |
| Lancaster General Hospital Ann B Barshinger Cancer Institute | Lancaster | Pennsylvania | 17601 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Kelsey Research Foundation | Houston | Texas | 77025 | — |
| Best Cancer Care & Hematology | Houston | Texas | 77089 | — |
| Lumi Research | Kingwood | Texas | 77339 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05198934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05198934 live on ClinicalTrials.gov.